Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma (NASDAQ: RPRX) has announced its participation in two major healthcare investor conferences in May 2025. The company will present at the BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET, and at the RBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET.
Both presentations will be available via webcast through Royalty Pharma's investor relations website and will remain archived for at least thirty days after the events.
Royalty Pharma (NASDAQ: RPRX) ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario previste per maggio 2025. L'azienda terr脿 una presentazione al BofA Securities 2025 Healthcare Conference mercoled矛 14 maggio alle 17:20 ET, e al RBC Capital Markets 2025 Global Healthcare Conference marted矛 20 maggio alle 16:05 ET.
Entrambe le presentazioni saranno disponibili in diretta streaming tramite il sito web delle relazioni con gli investitori di Royalty Pharma e resteranno archiviate per almeno trenta giorni dopo gli eventi.
Royalty Pharma (NASDAQ: RPRX) ha anunciado su participaci贸n en dos importantes conferencias para inversores del sector salud en mayo de 2025. La compa帽铆a realizar谩 una presentaci贸n en la BofA Securities 2025 Healthcare Conference el mi茅rcoles 14 de mayo a las 5:20 p.m. ET, y en la RBC Capital Markets 2025 Global Healthcare Conference el martes 20 de mayo a las 4:05 p.m. ET.
Ambas presentaciones estar谩n disponibles v铆a webcast a trav茅s del sitio web de relaciones con inversores de Royalty Pharma y permanecer谩n archivadas por al menos treinta d铆as despu茅s de los eventos.
Royalty Pharma (NASDAQ: RPRX)電� 2025雲� 5鞗旍棎 鞐措Μ電� 霊� 臧滌潣 欤检殧 項姢旒�鞏� 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃� 瓴冹瀯鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 5鞗� 14鞚� 靾橃殧鞚� 鞓ろ泟 5鞁� 20攵�(霃欕秬鞁滉皠)鞐� BofA Securities 2025 Healthcare Conference鞐愳劀, 5鞗� 20鞚� 頇旍殧鞚� 鞓ろ泟 4鞁� 5攵�(霃欕秬鞁滉皠)鞐� RBC Capital Markets 2025 Global Healthcare Conference鞐愳劀 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
霊� 氚滍憸 氇憪 Royalty Pharma 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞝滉车霅橂┌, 頄夓偓 膦呺 頉� 斓滌唽 30鞚缄皠 鞎勳勾鞚措笇搿� 雮晞 鞛堨姷雼堧嫟.
Royalty Pharma (NASDAQ : RPRX) a annonc茅 sa participation 脿 deux grandes conf茅rences pour investisseurs dans le secteur de la sant茅 en mai 2025. La soci茅t茅 pr茅sentera lors de la BofA Securities 2025 Healthcare Conference le mercredi 14 mai 脿 17h20 ET, ainsi qu'脿 la RBC Capital Markets 2025 Global Healthcare Conference le mardi 20 mai 脿 16h05 ET.
Les deux pr茅sentations seront accessibles en webcast via le site des relations investisseurs de Royalty Pharma et resteront archiv茅es pendant au moins trente jours apr猫s les 茅v茅nements.
Royalty Pharma (NASDAQ: RPRX) hat seine Teilnahme an zwei bedeutenden Gesundheitsinvestoren-Konferenzen im Mai 2025 angek眉ndigt. Das Unternehmen wird am BofA Securities 2025 Healthcare Conference am Mittwoch, den 14. Mai um 17:20 Uhr ET und am RBC Capital Markets 2025 Global Healthcare Conference am Dienstag, den 20. Mai um 16:05 Uhr ET pr盲sentieren.
Beide Pr盲sentationen werden per Webcast 眉ber die Investor-Relations-Website von Royalty Pharma verf眉gbar sein und mindestens drei脽ig Tage nach den Veranstaltungen archiviert bleiben.
- None.
- None.
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
- BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET / 2:20 p.m. PT
- RBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET
The webcasts will be accessible from Royalty Pharma鈥檚 鈥淓vents鈥� page at . Webcasts will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry鈥檚 leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly 鈥� directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma鈥檚 current portfolio includes royalties on more than 35 commercial products, including Vertex鈥檚 Trikafta, GSK鈥檚 Trelegy, Roche鈥檚 Evrysdi, Johnson & Johnson鈥檚 Tremfya, Biogen鈥檚 Tysabri and Spinraza, AbbVie and Johnson & Johnson鈥檚 Imbruvica, Astellas and Pfizer鈥檚 Xtandi, Novartis鈥� Promacta, Pfizer鈥檚 Nurtec ODT and Gilead鈥檚 Trodelvy, and 15 development-stage product candidates. For more information, visit .
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
FAQ
When is Royalty Pharma (RPRX) presenting at the BofA Securities Healthcare Conference 2025?
What time is Royalty Pharma's presentation at the RBC Capital Markets Healthcare Conference 2025?
How long will Royalty Pharma's (RPRX) conference webcasts be available?
Where can I watch Royalty Pharma's (RPRX) investor conference presentations?
